Cerebrospinal Fluid Neuromarker Levels in Patients With Schizophrenia and Healthy Control Participants: A Proximity Extension Assay Study.

Shinsuke Hidese, Kotaro Hattori, Takako Enokida, Megumi Tatsumi, Ryo Matsumura, Hiroshi Kunugi

Abstract read

In one paragraph

Article in Biological psychiatry global open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shinsuke HideseDepartment of Psychiatry, Teikyo University School of Medicine, Kaga, Tokyo, Japan.

Kotaro HattoriDepartment of Biobanking, Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.

Takako EnokidaDepartment of Biobanking, Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.

Megumi TatsumiDepartment of Biobanking, Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.

Ryo MatsumuraDepartment of Biobanking, Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.

Hiroshi KunugiDepartment of Psychiatry, Teikyo University School of Medicine, Kaga, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To further evaluate the association between cerebrospinal fluid (CSF) neuromarkers and schizophrenia, we measured CSF neuromarker levels using proximity extension assay (PEA) in patients with schizophrenia and healthy control (HC) participants. Methods: Participants included 97 patients with schizophrenia (mean age [SD] = 38.8 [10.3] years; 60 men and 37 women) and 71 HC participants (mean age [SD] = 46.9 [15.4] years; 42 men and 29 women). Symptoms in patients with schizophrenia were assessed using the Positive and Negative Syndrome Scale (PANSS). CSF protein levels were measured using the Olink PEA Neurology Panel. Results: CSF levels of cadherin 3, FcRL2, granzyme A, NAAA, plexin-B1, and sFRP-3 were lower in patients with schizophrenia than in HC participants ( Conclusions: This PEA study identified candidate CSF trait and state markers in schizophrenia; however, these findings require confirmation in further studies, as this was a primarily exploratory and hypothesis-generating study.

Indexed as

BiomarkersCerebrospinal fluidProteomicsProximity extension assaySchizophreniaSymptom severity

Identifiers

PMID42830830

DOI10.1016/j.bpsgos.2026.100804

PMCPMC13634075

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.